Mice deficient in LCN2 or treated with an LCN2 inhibitory monoclonal antibody shown a reduction in tumor growth and metastasis, attributed to the destabilization of the LCN2/MMP-9 complex, underscoring the potential of such interventions in addressing breast cancer brain metastasis (37). This evidence concerns the gene MMP9 and breast cancer.